[HTML][HTML] The intracellular signalosome of PD-L1 in cancer cells

D Escors, M Gato-Cañas, M Zuazo, H Arasanz… - Signal transduction and …, 2018 - nature.com
D Escors, M Gato-Cañas, M Zuazo, H Arasanz, MJ García-Granda, R Vera, G Kochan
Signal transduction and targeted therapy, 2018nature.com
Abstract Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells
accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First,
PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by
binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of
intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses
and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the …
Abstract
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
nature.com